FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891412296> ?p ?o ?g. }

• W2891412296 endingPage "1508" @default.
• W2891412296 startingPage "1499" @default.
• W2891412296 abstract "Information on the use of aspirin to increase healthy independent life span in older persons is limited. Whether 5 years of daily low-dose aspirin therapy would extend disability-free life in healthy seniors is unclear.From 2010 through 2014, we enrolled community-dwelling persons in Australia and the United States who were 70 years of age or older (or ≥65 years of age among blacks and Hispanics in the United States) and did not have cardiovascular disease, dementia, or physical disability. Participants were randomly assigned to receive 100 mg per day of enteric-coated aspirin or placebo orally. The primary end point was a composite of death, dementia, or persistent physical disability. Secondary end points reported in this article included the individual components of the primary end point and major hemorrhage.A total of 19,114 persons with a median age of 74 years were enrolled, of whom 9525 were randomly assigned to receive aspirin and 9589 to receive placebo. A total of 56.4% of the participants were women, 8.7% were nonwhite, and 11.0% reported previous regular aspirin use. The trial was terminated at a median of 4.7 years of follow-up after a determination was made that there would be no benefit with continued aspirin use with regard to the primary end point. The rate of the composite of death, dementia, or persistent physical disability was 21.5 events per 1000 person-years in the aspirin group and 21.2 per 1000 person-years in the placebo group (hazard ratio, 1.01; 95% confidence interval [CI], 0.92 to 1.11; P=0.79). The rate of adherence to the assigned intervention was 62.1% in the aspirin group and 64.1% in the placebo group in the final year of trial participation. Differences between the aspirin group and the placebo group were not substantial with regard to the secondary individual end points of death from any cause (12.7 events per 1000 person-years in the aspirin group and 11.1 events per 1000 person-years in the placebo group), dementia, or persistent physical disability. The rate of major hemorrhage was higher in the aspirin group than in the placebo group (3.8% vs. 2.8%; hazard ratio, 1.38; 95% CI, 1.18 to 1.62; P<0.001).Aspirin use in healthy elderly persons did not prolong disability-free survival over a period of 5 years but led to a higher rate of major hemorrhage than placebo. (Funded by the National Institute on Aging and others; ASPREE ClinicalTrials.gov number, NCT01038583 .)." @default.
• W2891412296 created "2018-09-27" @default.
• W2891412296 creator A5012502220 @default.
• W2891412296 creator A5015724516 @default.
• W2891412296 creator A5022309484 @default.
• W2891412296 creator A5023911162 @default.
• W2891412296 creator A5024230104 @default.
• W2891412296 creator A5029509408 @default.
• W2891412296 creator A5033034869 @default.
• W2891412296 creator A5033818609 @default.
• W2891412296 creator A5041942546 @default.
• W2891412296 creator A5044983885 @default.
• W2891412296 creator A5044990471 @default.
• W2891412296 creator A5048380539 @default.
• W2891412296 creator A5050901838 @default.
• W2891412296 creator A5052343370 @default.
• W2891412296 creator A5054368962 @default.
• W2891412296 creator A5057379795 @default.
• W2891412296 creator A5062338789 @default.
• W2891412296 creator A5064816095 @default.
• W2891412296 creator A5065807762 @default.
• W2891412296 creator A5068463698 @default.
• W2891412296 creator A5071210112 @default.
• W2891412296 creator A5076092828 @default.
• W2891412296 creator A5081383005 @default.
• W2891412296 creator A5082697210 @default.
• W2891412296 creator A5083061727 @default.
• W2891412296 creator A5083171777 @default.
• W2891412296 creator A5088410308 @default.
• W2891412296 date "2018-10-18" @default.
• W2891412296 modified "2023-10-12" @default.
• W2891412296 title "Effect of Aspirin on Disability-free Survival in the Healthy Elderly" @default.
• W2891412296 cites W128983294 @default.
• W2891412296 cites W1533850659 @default.
• W2891412296 cites W1972566357 @default.
• W2891412296 cites W1985770842 @default.
• W2891412296 cites W1986003353 @default.
• W2891412296 cites W2000808937 @default.
• W2891412296 cites W2006318999 @default.
• W2891412296 cites W2014091144 @default.
• W2891412296 cites W2024352468 @default.
• W2891412296 cites W2034942998 @default.
• W2891412296 cites W2050820265 @default.
• W2891412296 cites W2087242360 @default.
• W2891412296 cites W2100012557 @default.
• W2891412296 cites W2100089051 @default.
• W2891412296 cites W2109222450 @default.
• W2891412296 cites W2111175587 @default.
• W2891412296 cites W2137408480 @default.
• W2891412296 cites W2138597449 @default.
• W2891412296 cites W2163046537 @default.
• W2891412296 cites W2164096839 @default.
• W2891412296 cites W2188507800 @default.
• W2891412296 cites W2332455909 @default.
• W2891412296 cites W2333990647 @default.
• W2891412296 cites W2399388987 @default.
• W2891412296 cites W2588728606 @default.
• W2891412296 cites W2626529212 @default.
• W2891412296 cites W2766278264 @default.
• W2891412296 cites W2767842448 @default.
• W2891412296 cites W2889884522 @default.
• W2891412296 cites W2892288854 @default.
• W2891412296 cites W4245466284 @default.
• W2891412296 doi "https://doi.org/10.1056/nejmoa1800722" @default.
• W2891412296 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6426126" @default.
• W2891412296 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30221596" @default.
• W2891412296 hasPublicationYear "2018" @default.
• W2891412296 type Work @default.
• W2891412296 sameAs 2891412296 @default.
• W2891412296 citedByCount "342" @default.
• W2891412296 countsByYear W28914122962018 @default.
• W2891412296 countsByYear W28914122962019 @default.
• W2891412296 countsByYear W28914122962020 @default.
• W2891412296 countsByYear W28914122962021 @default.
• W2891412296 countsByYear W28914122962022 @default.
• W2891412296 countsByYear W28914122962023 @default.
• W2891412296 crossrefType "journal-article" @default.
• W2891412296 hasAuthorship W2891412296A5012502220 @default.
• W2891412296 hasAuthorship W2891412296A5015724516 @default.
• W2891412296 hasAuthorship W2891412296A5022309484 @default.
• W2891412296 hasAuthorship W2891412296A5023911162 @default.
• W2891412296 hasAuthorship W2891412296A5024230104 @default.
• W2891412296 hasAuthorship W2891412296A5029509408 @default.
• W2891412296 hasAuthorship W2891412296A5033034869 @default.
• W2891412296 hasAuthorship W2891412296A5033818609 @default.
• W2891412296 hasAuthorship W2891412296A5041942546 @default.
• W2891412296 hasAuthorship W2891412296A5044983885 @default.
• W2891412296 hasAuthorship W2891412296A5044990471 @default.
• W2891412296 hasAuthorship W2891412296A5048380539 @default.
• W2891412296 hasAuthorship W2891412296A5050901838 @default.
• W2891412296 hasAuthorship W2891412296A5052343370 @default.
• W2891412296 hasAuthorship W2891412296A5054368962 @default.
• W2891412296 hasAuthorship W2891412296A5057379795 @default.
• W2891412296 hasAuthorship W2891412296A5062338789 @default.
• W2891412296 hasAuthorship W2891412296A5064816095 @default.
• W2891412296 hasAuthorship W2891412296A5065807762 @default.
• W2891412296 hasAuthorship W2891412296A5068463698 @default.
• W2891412296 hasAuthorship W2891412296A5071210112 @default.

• next